Seeking synergy for novel weight- and glucose-lowering pharmacotherapy and exercise training in heart failure patients with preserved ejection fraction
Every "GLP-1 patch" sold online in 2026 is a dietary supplement sticker
N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I
Retatrutide has not been approved by the MHRA, EMA, or FDA
The GLP-1/glucagon agonist cotadutide (MEDI0382) is the compound of this dual-receptor agonist class that is the most advanced in clinical development
Females predominated (n = 18,907, 65.3%) over males (n = 8,838, 30.5%)